Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPRF | P10586 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10366049 | 0.94 | KDM4E (0.35) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975823 | 0.93 | CHRM5 (0.42) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975819 | 0.91 | CHRM2 (0.34) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975674 | 0.90 | ALDH1A1 (0.36) | CD274CHRM5CHRM1CHRM2CHRM4 | |
| SCHEMBL9941374 | 0.90 | CHRM2 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10364959 | 0.90 | CHRM3 (0.36) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9975717 | 0.90 | ACHE (0.38) | CHRM5CHRM1CHRM2CHRM3ALDH1A1 | |
| SCHEMBL9975704 | 0.89 | ACHE (0.41) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL10323778 | 0.88 | CHRM5 (0.35) | CHRM5CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL9941488 | 0.88 | ALDH1A1 (0.38) | CHRM5CHRM1CHRM2CHRM4CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | POLR2E, POLR2H, GTF3C3 | CD274 4468/4885CHRM5 4121/4885CHRM1 3102/4885 |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | CD274 3925/4885CHRM5 3426/4885CHRM1 1499/4885 |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2E, POLR2H, GTF3C3 | CD274 4468/4885CHRM5 4121/4885CHRM1 3102/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | CD274 4468/4885CHRM5 4121/4885CHRM1 3102/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | CD274 3925/4885CHRM5 3426/4885CHRM1 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.